From the Barrow Pituitary Center, Barrow Neurological Institute and St. Joseph's Hospital and Medical Center, University of Arizona College of Medicine and Creighton School of Medicine, Phoenix, Arizona.
Department of Neurosurgery, University of California San Francisco, California Center for Pituitary Disorders, San Francisco, California.
Endocr Pract. 2020 Aug;26(8):915-922. doi: 10.4158/EP-2020-0308.
In December 2019, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of coronavirus disease 2019 (COVID-19) that resulted in a global pandemic with substantial morbidity and mortality. Currently, there is no specific treatment or approved vaccine against COVID-19. The underlying associated comorbidity and diminished immune function of some pituitary patients (whether caused by the disease and its sequelae or treatment with excess glucocorticoids) increases their risk of contracting and developing complications from COVID-19 infection.
A review of studies in PubMed and Google Scholar published between January 2020 to the time of writing (May 1, 2020) was conducted using the search terms 'pituitary,' 'coronavirus,' 'COVID-19', '2019-nCoV', 'diabetes mellitus', 'obesity', 'adrenal,' and 'endocrine.'
Older age and pre-existing obesity, hypertension, cardiovascular disease, and diabetes mellitus increase the risk of hospitalization and death in COVID-19 patients. Men tend to be more severely affected than women; fortunately, most men, particularly of younger age, survive the infection. In addition to general comorbidities that may apply to many pituitary patients, they are also susceptible due to the following pituitary disorder-specific features: hypercortisolemia and adrenal suppression with Cushing disease, adrenal insufficiency and diabetes insipidus with hypopituitarism, and sleep-apnea syndrome and chest wall deformity with acromegaly.
This review aims to focus on the impact of COVID-19 in patients with pituitary disorders. As most countries are implementing mobility restrictions, we also discuss how this pandemic has affected patient attitudes and impacted our decision-making on management recommendations for these patients.
ACE = angiotensin-converting enzyme; AI = adrenal insufficiency; ARB = angiotensin receptor blocker; ARDS = acute respiratory disease syndrome; COVID-19 = coronavirus disease 2019; CPAP = continuous positive airway pressure; DI = diabetes insipidus; DM = diabetes mellitus; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
2019 年 12 月,一种名为严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的新型冠状病毒引发了 2019 年冠状病毒病(COVID-19)疫情,导致了全球大流行,发病率和死亡率都很高。目前,尚无针对 COVID-19 的特定治疗方法或批准的疫苗。一些垂体患者的合并症和免疫功能下降(无论是由疾病及其后遗症引起,还是由过量使用糖皮质激素引起),增加了他们感染 COVID-19 并出现并发症的风险。
使用“垂体”、“冠状病毒”、“COVID-19”、“2019-nCoV”、“糖尿病”、“肥胖症”、“肾上腺”和“内分泌”等关键词,在 PubMed 和 Google Scholar 上检索了 2020 年 1 月至写作时(2020 年 5 月 1 日)发表的研究。
年龄较大、肥胖、高血压、心血管疾病和糖尿病会增加 COVID-19 患者住院和死亡的风险。男性比女性更容易受到严重影响;幸运的是,大多数男性,尤其是年轻男性,能够从感染中存活下来。除了可能适用于许多垂体患者的一般合并症外,由于以下垂体疾病特异性特征,他们也容易受到影响:库欣病的皮质醇增多症和肾上腺抑制,垂体功能减退症的肾上腺功能不全和尿崩症,以及肢端肥大症的睡眠呼吸暂停综合征和胸廓畸形。
本综述旨在重点关注 COVID-19 对垂体疾病患者的影响。由于大多数国家都在实施流动限制,我们还讨论了这场大流行如何影响患者的态度,并对我们对这些患者管理建议的决策产生了影响。
ACE = 血管紧张素转换酶;AI = 肾上腺功能不全;ARB = 血管紧张素受体阻滞剂;ARDS = 急性呼吸窘迫综合征;COVID-19 = 2019 年冠状病毒病;CPAP = 持续气道正压通气;DI = 尿崩症;DM = 糖尿病;SARS-CoV-2 = 严重急性呼吸综合征冠状病毒 2。